Glycosylated metal chelators as anti-parasitic

agents with tunable selectivity by Reddy, Andrew et al.
Dalton
Transactions
PAPER
Cite this: Dalton Trans., 2017, 46,
5297
Received 6th December 2016,
Accepted 27th March 2017
DOI: 10.1039/c6dt04615k
rsc.li/dalton
Glycosylated metal chelators as anti-parasitic
agents with tunable selectivity†
Andrew Reddy, a Leandro Stefano Sangenito,b Arthur de Azevedo Guedes,b
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Trypanosoma cruzi and Leishmania amazonensis are the causative agents of Chagas’ disease and leish-
maniasis, respectively. These conditions affect millions of people worldwide, especially in developing
countries. As such, there is an urgent need for novel, efficient and cost-effective treatments for these dis-
eases, given the growing resistance and side-effects of current therapies. This work details the synthesis
and evaluation of the anti-parasitic activity of novel amino- and iminopyridyl metal chelators, their glyco-
sylated derivatives and some of their metal complexes. Our results revealed the potent and metal-depen-
dent activity for the aminopyridyl compounds: Cu(II) complexes were most effective against T. cruzi trypo-
mastigotes, while Zn(II) complexes presented excellent activity against L. amazonensis promastigotes. In
addition, the compounds showed excellent selectivity indexes and very low relative toxicity as judged by
in vitro and in vivo studies, respectively, using RAW macrophages and Galleria mellonella larvae model.
Introduction
Neglected tropical diseases (NTD) affect in excess of 1 billion
people in the most impoverished areas of the world, causing
more than 500 000 deaths every year.1 Of the major NTDs, the
kinetoplastid parasite diseases leishmaniasis and Chagas
disease (CD) are considered among the most challenging to
tackle due to their high mortality rates and extremely limited
treatment options.2,3
CD is a chronic, debilitating parasitic disease caused by
Trypanosoma cruzi and is transmitted by blood-sucking insects of
the subfamily Triatominae.4 The disease is a significant health-
care problem and is estimated to infect more than 10 million
people worldwide and presents a substantial socioeconomic
burden in addition to a high morbidity rate.1 The current treat-
ments for CD are nifurtimox and benznidazole, both of which
present undesirable side effects and limited efficacy in chronic
patients.5,6 Moreover, there is a growing resistance of T. cruzi
towards these treatments which further necessitates novel thera-
peutics without cross resistance with currently used drugs.7,8
Leishmaniasis is a group of tropical diseases resulting
from infection of parasites of the genus Leishmania and pre-
sents a substantial healthcare problem worldwide.9
Leishmaniasis occurs in several forms, the most severe of
which is visceral leishmaniasis (VL) which accounts for
nearly 500 000 of the 2 million cases of leishmaniasis
reported annually and is fatal if left untreated.10 VL is caused
by the infection of the host’s macrophages with Leishmania
amastigotes following infection with promastigotes which are
transmitted by the female sand fly.11 First line treatment typi-
cally employs pentavalent antimonials such as sodium stibo-
gluconate. However, there is widespread resistance to these
compounds which leads to the use of amphotericin B as the
preferred treatment for VL.12–14 Unfortunately, the use of this
drug in endemic regions is limited by its cost, toxicity and
difficulties of administration.15 These challenges demon-
strate the urgent need for novel, safe and cost-effective thera-
pies for these diseases. In particular, drugs with activity
against multiple kinetoplastid parasites are especially attrac-
tive due to their broad spectrum of activity.16
Metallodrugs are an emerging therapeutic approach in the
treatment of parasitic diseases.17,18 Accordingly, several metal
complexes have been investigated against CD and
leishmaniasis.4,19–21 The combination of metal ions with
drugs and organic ligands can enhance their activity while at
the same time, reducing the toxicity and undesired side effects
that metal ions on their own could impart.22–24
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In this study, the synthesis of a series of amino- and imino-
pyridyl ligands and some of their metal complexes is reported.
In addition, their anti-parasitic activity against L. amazonensis
promastigotes and T. cruzi trypomastigotes is evaluated. With
a view to further improve their selectivity and bioavailability,
the synthesis and assessment of the anti-parasitic activity of
some per-acetylated glucosyl analogues has also been per-
formed. Carbohydrate conjugation is an attractive means of
improving the selectivity of bioactive molecules through a tar-
geting strategy.25,26 However, the water-soluble character of
saccharides can compromise their ability to cross cellular
membranes. Therefore, the use of acetylated sugars, with
increased hydrophobicity, which undergo hydrolysis after
administration is often preferred.27 Thus, the glycosylation of
metal chelators seems a logical approach to enhance their
therapeutic potential.28
Results and discussion
Synthesis
The synthesis of the aminopyridyl ligands 2a 29 and 2b (N2
series, Scheme 1a) was achieved by the reductive amination of
aldehydes 1a and 1b,30 respectively. The reduction of the
corresponding imines was carried out in situ since they were
found to be very sensitive to hydrolysis. The metal complexes
studied were obtained by the direct reaction of ethanolic solu-
tions of the ligands and metal salts. Complexes with Cu(II)
(1 : 1 complexes 3a and 3b) were formed from ligands 2a and
2b, while the complex of 2a with Zn(II) was formed in a 2 : 1
stoichiometry (complex 4).
Crystals suitable for X-ray crystallography of 3a were
obtained from a solution of the complex in acetonitrile. This
was found to contain two distinct 5-coordinate Cu(II) species;
an acetonitrile adduct [Cu(2a)(CH3CN)Cl2] (Fig. 1A) encapsu-
lated inside a unit cell with a binuclear bridged species
[Cu2(2a)2Cl2(μ2-Cl)2] (Fig. 1B) occupying the vertices (see also
ESI-1.1†).
In the mononuclear species, the ligand 2a is coordinated in
a bidentate fashion with a bite angle of 82.60°. The Cu–Npyr
and Cu–Namine are bonded at distances of 2.025 Å and 2.046 Å
respectively, while acetonitrile adduct shows a Cu–NMeCN bond
length of 2.302 Å.
The chloride ligands are coordinated symmetrically with
Cu–Cl bonds of 2.313 Å. The structure has a τ5 value of 0.07
corresponding to a square pyramidal geometry.31 There is a
short range interaction of 3 Å between the Cu(II) coordination
centre and a chloride ligand of a neighbouring molecule.
The dimer on the other hand shows a bond length of
2.257 Å for the axial Cu–Cl bond while the bridging Cu–Cl
bonds are asymmetrically elongated with lengths of 2.302 Å
and 2.692 Å. 2a binds more tightly to the metal centre com-
pared to the mononuclear complex with lengths of 2.010 Å and
2.036 Å for the Cu–Npyr and Cu–Namine interactions and a
slightly smaller bite angle of 82.25°. This molecule has a τ5
value of 0.15 which indicates a higher degree of distortion
from the ideal square pyramidal geometry than the mono-
nuclear acetonitrile adduct described above. As the elemental
analysis of the compound indicates the presence of a water
molecule, it is likely that the material obtained is a 5-coordi-
nate complex analogous to the acetonitrile adduct with water
occupying the axial position in place of the acetonitrile ligand.
We examined the stability of the Cu(II) complex 3a by
recording UV/Vis spectra of a solution of 3a in DMSO/water a
0 h, 24 h and 72 h. No appreciable changes were observed
(Fig. 2.1-ESI†). We also examined the stability of the Zn(II)
complex 4 by recording 1H NMR spectra of a solution of 4 in
d6-DMSO/D2O a 0 h and 72 h (Fig. 2.2-ESI†) and again, no
appreciable changes were observed.
Contrary to the N2 compounds, the imine ligands corres-
ponding to the N2O series (Scheme 1b) were readily prepared
Scheme 1 Synthesis of (a) aminopyridyl ligands (N2 series) and (b) imi-
nopyridyl (N2O series) ligands and some of their metal complexes.
Reagents and conditions: (i) 2-picolylamine, ethanol, MgSO4, 80 °C, 4 h;
(ii) NaBH4, ethanol/acetic acid, −10 °C to rt, 16 h; (iii) CuCl2·2H2O,
ethanol, rt, 16 h; (iv) Zn(ClO4)2·6H2O, ethanol, rt; (v) 2-picolylamine,
ethanol, rt, 4–6 h; (vi) Cu(ClO4)2·2H2O, ethanol, 5 h.
Fig. 1 X-ray crystal structures of 3a with atomic displacement para-
meters shown at 50% probability. Hydrogen atoms omitted for clarity.
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by the direct reaction of 2-picolylamine with aldehydes 5a–d
without the need for acid catalysis or desiccating agents. The
presence of the ortho hydroxyl group provides a favourable
hydrogen bond interaction with the imine lone pair of elec-
trons which results in the shifting of the 1H NMR resonance of
the ortho phenolic protons of imines 6b–d to 13–14 ppm from
11.4 ppm in the precursor aldehydes. This hydrogen bonding
is also observed in the crystal structures of 6a and 6c (ESI-1.2
and 1.3†) and confers an unusual stability on these imines
and a remarkable resistance to hydrolysis, even when stored
under ambient conditions.
Preliminary investigations into the optimum experimental
conditions for the synthesis of metal complexes with ligands
of the N2O series focused on those for ligand 6a. The Cu(II)
and Zn(II) complexes, 7 and 8, respectively, presented a 1 : 1
stoichiometry. However, it was observed by NMR spectroscopy
that Zn(II) complex 8 was unstable in solution and hydrolyzes
to the aldehyde 5a and the bis(2-picolylamine)zinc perchlorate
complex 9. The identity of this compound was confirmed by
NMR and X-ray crystallography of the crystals obtained from
the NMR sample of 8 in d8-THF (Fig. 2, see also ESI-1.4†).
Interestingly, this adopts an unusual coordination geometry
with a τ′4 value of 0.70 which suggests a distorted see-saw
structure (τ′4: 0.64). This is consistent with previously reported
see-saw structures which exhibit τ′4 values of 0.70 ± 0.02.
32,33
This geometry has only been reported once in the literature for
a zinc compound which contained Zn(0)34 and, to the best of
our knowledge, it has not been yet reported for a Zn(II)
complex. Complex 9 can also be synthesized by the direct reac-
tion of 2-picolyamine and Zn(ClO4)2·6H2O. The NMR data of
the hydrolysis product was identical to that of the complex 9
synthesized purposely. The analogous Cu(II) complex 7 exhibits
a much greater stability in solution at room temperature.
However, the corresponding Cu(II) picolylamine complex
[Cu(2-picolylamine)2(ClO4)2]
35 can be formed by refluxing the
complex 7 for 24 h in ethanol, causing the hydrolysis of the
ligand. The 2-picolylamine ligands in the Cu(II) picolylamine
complex were reported to coordinate in an anti fashion while
crystallographic data showed the ligands in Zn(II) complex 9
binding in a syn manner.
Evaluation of in vitro cytotoxicity to macrophage cells
A library of eleven compounds (Fig. 3) was initially screened to
test the cytotoxicity of the compounds. They were administered
to murine macrophages and their viability was estimated
using the MTT assay in order to determine the cytotoxicity con-
centration (CC50). The simple metal salts CuCl2·2H2O and
ZnCl2 did not show significant toxicity, with activities compar-
able to the control. All of the compounds exhibited low toxicity
towards RAW cells (Fig. 3.1-ESI†) with complex 3a presenting
the highest toxicity (106.2 μM). In contrast, the least toxic com-
pound was Zn(II) complex 8 which exhibited a CC50 above the
highest concentration used (400 μM); however, given that this
compound was found to hydrolyze in DMSO, it is likely that
any activity observed is due to the hydrolysis products. These
data suggests that both amino- and iminopyridyl derivatives
are well tolerated by mammalian cells.
Anti-T. cruzi activity
The anti-parasitic activity of the ligands and their metal com-
plexes was then evaluated. The library of compounds was
initially screened for inhibitory activity against the viability of
T. cruzi trypomastigotes at a concentration of 50 μM. Seven
compounds (2a–b, 3a–b, 4, 6b, 7) significantly reduced the via-
bility of T. cruzi (Fig. 4A). The simple metal salts CuCl2·2H2O
and ZnCl2 showed similar activity to the control. All members
of the N2 series showed activity, while from the N2O series,
Fig. 2 Molecular structure of 9 with atomic displacement parameters
shown at 50% probability. Hydrogen atoms omitted for clarity. Only
symmetry unique atoms are labelled. Perchlorate oxygen atoms are
modelled in two positions with occupancies of 69/31%.
Fig. 3 Chemical structure of the amino- and iminopyridyl ligands and
metal complexes evaluated for anti-parasitic activity.
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only the glycosylated ligand 6b and the Cu(II) complex 7 were
active. All of the compounds were then tested at 10 μM
(Fig. 4B) and the LD50 values of the most active compounds
were determined (Fig. 4C and Table 1). The Cu(II) complexes
3a–b (LD50 values of 1.7 and 1.8 μM, respectively) showed sig-
nificantly better efficacy than the current clinical drug benzni-
dazole (LD50 value 3.8 μM) towards T. cruzi, while the non
metallated ligands 2a–b and the Zn(II) complex 4 (LD50 values
4.6, 5.3, 5.2 μM, respectively) showed comparable activity.
The effect of the active compounds on the morphology of
T. cruzi was then evaluated. Compounds from the N2 series
(2a–b, 3a–b, 4) were administered to the parasite at their LD50
concentrations and cell morphology was inspected by means
of optical microscopy after 24 h exposure (Fig. 5). Non-treated
trypomastigote cells retained their typical elongated shape, in
which the flagellum is attached along the length of the para-
Fig. 4 Effects of amino/iminopyridyl derivatives on the viability of
T. cruzi trypomastigotes. (A) Viability rate of trypomastigotes (initial
inoculum of 106 cells per mL) at 37 °C in absence/presence of the com-
pounds (50 µM). The parasites were counted 24 h after addition of the
compounds; inset: control with the simple Cu(II) and Zn(II) salts. (B)
Compounds screened at 10 µM as described in A. (C) Cell death profile
with selected compounds at appropriated concentrations (0.1 to 10 µM).
The viable parasites were counted by Trypan blue exclusion and motility
in a Neubauer chamber after 24 h of incubation. Benznidazole was used
as a positive control. Results are expressed as number of viable cells.
DMSO (solvent used), was used as a control and did not affect the para-
site viability (data not shown). Data shown are the mean ± standard
deviation of three independent experiments performed in triplicate. The
symbols represent the significant differences in relation to the control
(P < 0.01).
Fig. 5 Effect of selected compounds on the morphology of T. cruzi try-
pomastigotes. Giemsa-stained smears of trypomastigotes were prepared
after incubation in the presence of each compound at LD50 concen-
tration for 24 h. Non-treated trypomastigotes (control) present a kineto-
plast (k), a central nucleus (n) and a flagellum (f ) attached to the parasite
cell body. Compound administration induced numerous morphological
changes, such as parasites becoming round in shape with reduced cell
size (arrowhead), swelling of the cell body (black thin arrow), and short-
ening or loss of flagellum (white arrow). All images are shown in the
same scale (bar = 10 µm).
Table 1 Selectivity indexes (SI) of compounds exhibiting the highest anti-parasitic activity
Compd
RAW CC50 T. cruzi LD50 L. amazonensis IC50 RAW/T. cruzi RAW/L. amazonensis
[µM] SI
2a 155.4 4.6 25.3 33.8 6.1
2b 234.5 5.3 7.1 44.2 33
3a 106.2 1.7 — 62.5 —
3b 127.6 1.8 — 70.9 —
4 118.2 5.2 1.3 22.7 90.9
6b 196.1 — 18.4 — 10.7
8 >400 — 17.1 — >23.4
Benznidazole 182.1 3.8 — 47.9 —
Amphotericin B 37.4 — 0.012 — 3.116
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site cell body, with an undulating membrane provided by fla-
gellum movement and an unaltered surface. The treatment of
trypomastigotes with the test compounds caused some signifi-
cant morphological changes when compared to the typical
appearance of non-treated parasites, including rounding in
shape with reduced cell size, swelling of the cell body and
shortening or loss of flagellum (Fig. 5).
Anti-L. amazonensis activity
The ability of the compounds to inhibit the proliferation of
L. amazonensis promastigotes was then evaluated. Firstly, the
compounds were screened at initial concentrations of 50 and
10 μM, respectively (Fig. 6A and B). Only compounds 2a–b, 4,
6b and 8 showed inhibitory effects on promastigote prolifer-
ation. The Zn(II) complex 4 from the N2 ligand series had the
highest activity, whilst the hydrolysis products of Zn(II)
complex 8 had comparable activity to those of the glycosylated
ligands 2b and 6b. As observed in the previously discussed bio-
logical assays, the simple metal salts CuCl2·2H2O and ZnCl2
had no anti-parasitic effect. The five most active compounds
were then tested across a range of concentrations to establish
the IC50 values (Fig. 6C and Table 1). All the compounds
showed dose-dependent activities: the activity of free ligand 2a
(IC50 = 25.3 μM) was greatly enhanced by the presence of Zn(II)
in complex 4 (IC50 = 1.3 μM) and, to a lesser extent, by conju-
gation to glucose, as evidenced by activity of 2b (IC50 =
7.1 μM). On the other hand, the compounds from the N2O
series showed similar activities, with IC50 values of 17.1 μM for
the hydrolysis products of Zn(II) complex 8 and 18.4 μM for gly-
cosylated ligand 6b. These results highlight the potential for
development of the active compounds, especially when
considering the severe toxicity of current treatments for
leishmaniasis.
As with T. cruzi, the L. amazonensis parasites were inspected
using light microscopy 72 h after the administration of each
compound at its IC50 value (Fig. 7). Untreated promastigotes
exhibited their typical elongated shape with a long flagellum
emerging at the anterior end of the parasite. The treated para-
sites displayed significant changes to their morphology when
compared to these control cells. These changes include loss of
flagellum and a reduced cell size. Further morphological
alterations, such as a swelling and rounding of the cell, were
also observed.
Evaluation of in vivo cytotoxicity to Galleria mellonella larvae
The active compounds 2a–b, 3a–b, 4, 6a–b and 8 were also
screened for toxicity against larvae of G. mellonella, a model
organism used as a surrogate to probe the response of the
human innate immune system.36–39 Compounds were admi-
nistered at concentrations of 1, 10 and 100 μM and the viabi-
lity of the larvae was assessed at 24 and 48 h. All of the larvae
treated with the compounds survived and none of those dis-
played any melanization of their cuticle, which is indicative of
an immune response (Fig. 3.2-ESI†).
Overall, these results indicate that the compounds from the
N2 series (aminopyridyl derivatives) are more effective anti-
parasitic agents than their corresponding iminopyridyl deriva-
tives (N2O series). Considering the anti-T. cruzi activities, the
selectivity indexes for the Cu(II) complexes 3a–b (62.5 and 70.9,
respectively, Table 1) are significantly higher than that for
reference drug benznidazole (47.9), currently used in the treat-
ment for CD. Other Cu(II) complexes with known drugs, like
risedronate or levofloxacin40,41 present IC50 values as low as
1.6 μM, however the corresponding selectivity indexes were as
high as 19.4 While there are some examples of Cu(II) complexes
capable of inhibiting the growth of T. cruzi,24,40–43 our results
represent a marked improvement in the development of selec-
Fig. 6 Effects of amino/iminopyridyl derivatives on the proliferative rate
of L. amazonensis promastigotes. (A) The proliferation of promastigotes
(initial inoculum of 105 cells per mL) was followed at 28 °C in absence/
presence of the compounds (50 µM). The parasites were counted 72 h
after addition of the compounds; inset: control with the simple Cu(II)
and Zn(II) salts. (B) Compounds screened at 10 µM as described in (A).
(C) Cell proliferation profile with selected compounds at appropriated
concentrations (0.1 to 50 µM). The viable parasites were counted by
Trypan blue exclusion and motility in a Neubauer chamber after 72 h of
incubation. Amphotericin B was used as a positive control. Results are
expressed as number of viable cells. DMSO (solvent used), was used as a
control and did not affect the parasite viability (data not shown). Data
shown are the mean ± standard deviation of three independent experi-
ments performed in triplicate. The symbols represent the significant
differences in relation to the control (P < 0.01).
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tive Cu(II)-based therapies for CD. It seems clear that Cu(II)
coordination enhances the anti-parasitic activity of the ligands:
a reduction in the IC50 value of the free ligand 2a from 4.6 μM
to 1.7 μM for complex 3a was observed (a 2.7-fold decrease); the
glucosylated ligand 2b presents an IC50 value of 5.3 μM while
the corresponding Cu(II) complex 3b has 1.8 μM (a 2.9-fold
decrease). This moderate improvement in the activity suggests
that metal complexation does not prompt the synergistic
effects as reported for some anti-trypanosomal complexes.
These effects are characterized by a dramatic increase in ligand
activity upon metal coordination.23 In our case it seems more
likely that Cu(II) provides additional affinity for the target
binding site(s), which would explain the slight increase in
activity compared to the ligands on their own. The Zn(II)
complex 4, with a 2 : 1 stoichiometry, possesses coordination
environment and molecular geometry rather different to the
Cu(II) complexes, which may not be so favourable for binding
with the target and could therefore account for the reduced
activity (5.2 μM). Some of the anti-trypanosomal Cu(II) com-
plexes reported in the literature bind to DNA, which could lead
to their anti-parasitic activity.41,42 A common structural feature
of these is the presence of a dinitrogen chelating motif, such as
1,10-phenanthroline and 2,2′-bipyridine, which are known cyto-
toxic agents.41–44 However, the compounds described herein
lack the extended aromatic planar surfaces required for
efficient DNA intercalation. The high tolerance of the N2 ligand
scaffolds, as evidenced by their high selectivity indexes
(Table 1) and the G. mellonella assays suggest that, from a struc-
tural perspective, the compounds are not likely to effect high
affinity DNA binding. However, further studies would be
necessary in order to determine their mechanism of action.
The influence of the coordinated metal in the anti-parasitic
activities is more evident considering the results from the anti-
leishmanial assays. In this case, none of the Cu(II) complexes
evaluated was able to inhibit the proliferation of
L. amazonensis promastigotes. On the other hand, the Zn(II)
complex 4 showed a remarkably low IC50 value of 5.2 μM
together with a selectivity index of 90.9. Zn(II) species have
been used to treat cutaneous leishmaniasis as both nutritional
supplements and topical drugs.45,46 Zn(II) complexes featuring
the 2-picolylamine binding motif have been recently reported
to inhibit the growth of L. major, with good activity in vivo.47
We found that the hydrolysis products from complex 8, namely
Zn(II) complex 9, also showed anti-parasitic activity to some
extent (17.1 μM). Several modes of action for Zn(II) complexes
with anti-leishmanial properties have been discussed in the lit-
erature: some compounds have been reported to inhibit
enzymes essential for the parasite’s carbohydrate metabolism,
such as those involved in the Embden–Meyerhof pathway.48
Some studies have indicated that Zn(II) complexes selectively
recognize anionic cell surfaces through a combination of
electrostatic attraction and specific coordination of the zinc
cations with phospholipids in the cell membrane.49,50 Given
the changes in parasite morphology effected by the Zn(II) com-
plexes described herein resulting in loss of the distinct shape
of the parasite, a structural component of the parasite mem-
brane could be proposed as a plausible target. However, in
depth studies, including TEM imaging, are necessary in order
to ascertain this hypothesis. It should be also noted that gluco-
sylated ligands 2b and 6b showed significant anti-leishmanial
activities (7.1 μM and 18.4 μM, respectively). The mechanism
of action of these ligands maybe multifunctional, and further
investigations are required in order to elucidate it. Finally,
compounds 6c, in which the phenolic hydroxyl has been alkyl-
ated and 6d, its glucosylated analogue, showed low activity
against both of the parasites studied in this work. This high-
lights the importance of the phenolic glycoside structural
feature for the biological activity of the compounds, suggesting
that only glycosylated compounds susceptible to the action of
glucosidases would show anti-parasitic activity.
Conclusions
In summary, a collection of amino- (N2) and iminopyridyl
(N2O) ligands, their glucosylated analogues and some of their
divalent metal complexes have been synthesized and their
anti-parasitic activity towards T. cruzi and L. amazonensis evalu-
ated. The compounds from the N2 series were found to be
more active than their corresponding N2O analogues. The
nature of the metal ion strongly influences the biological
activities of the complexes investigated: Cu(II) complexes 3a
and 3b showed potent activity against T. cruzi while the Zn(II)
complex 4 was most efficient at inhibiting the growth of
L. amazonensis. Moreover, the most potent compounds pre-
sented remarkable selectivity indexes; in particular, the anti-
trypanosomal compounds were considerably higher than the
control drug currently in use for the treatment of CD. These
preliminary studies suggest that these compounds could be
Fig. 7 Effect of selected compounds on the morphology of
L. amazonesis. Giemsa-stained smears of promastigotes were prepared
after incubation in the presence of each compound at LD50 concen-
tration for 72 h. Non-treated promastigotes (control) present a kineto-
plast (k), a central nucleus (n) and a flagellum (f ) attached to the parasite
cell body. The treatment induced morphological changes, such as para-
sites becoming round in shape with/or reduced cell size (arrowhead),
swelling of the cell body (black thin arrow) and loss of flagellum (white
arrow). All images are shown in the same scale (bar = 10 μm).
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extremely attractive candidates for further development as
novel anti-kinetoplastid therapeutic agents.
Experimental
Chemistry general methods
All chemicals purchased were reagent grade and used without
further purification unless stated otherwise. Dichloromethane
and acetonitrile were freshly distilled over CaH2 prior use.
Ethanol was dried over 3 Å molecular sieves, which were flame
dried, prior to use. Reactions were monitored with thin layer
chromatography (TLC) on Merck Silica Gel F254 plates.
Detection was effected by UV or charring in a mixture of 5%
sulfuric acid–ethanol. All glassware used for anhydrous reac-
tions was flame dried under vacuum prior to use. NMR spectra
were obtained on a Bruker Ascend 500 using the residual
solvent peak as internal standard. Chemical shifts are reported
in ppm. Flash chromatography was performed with Merck
Silica Gel 60. Microwave reactions were carried out using a
CEM Discover Microwave Synthesizer. Optical rotations were
obtained from an AA-100 polarimeter. [α]D values are given in
10−1 cm2 g−1. The melting points were obtained using a Stuart
Scientific SMP1 melting point apparatus and are uncorrected.
Purity was confirmed by elemental analysis using a FLASH EA
1112 Series Elemental Analyzer with Eager 300 operating soft-
ware. High resolution mass spectrometry (HRMS) was per-
formed on an Agilent-LC 1200 Series coupled to a 6210 Agilent
Time-Of-Flight (TOF) mass spectrometer equipped with an
electrospray source in both positive and negative (ESI+/−)
modes. Magnetic susceptibility measurements were carried
out at rt using a Johnson Matthey Magnetic Susceptibility
Balance with [HgCo(SCN)4] as reference. Infrared spectra were
obtained as a film on NaCl plates or as KBr disks in the region
4000–400 cm−1 on a PerkinElmer Spectrum 100 FT-IR spectro-
photometer. Purity of tested compounds was 95% or higher,
as determined by elemental analysis (results within 0.4% of
theoretical values). Caution: Although not encountered in our
experiments, perchlorate salts of metal ions are potentially
explosive and should be manipulated with care.
Synthesis
Compounds 1b,30 2a,29 5b,51 5c 52 have been previously
reported. For optimized synthetic procedures and complete
characterization, see ESI.†
N-{[4-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)pheny]
lmethyl}-2-pyridinemethamine (2b). 1b (1 g, 2.2 mmol) and
2-picolylamine (0.24 mL, 2.2 mmol) were stirred in ethanol
(25 mL) with anhydrous MgSO4 (0.8 g, 6.6 mmol) at 80 °C for
4 h under a nitrogen atmosphere. The mixture was filtered and
cooled to −10 °C in an ice/acetone/NaCl bath under nitrogen.
Acetic acid (0.12 mL, 2.2 mmol) was added immediately fol-
lowed by the dropwise addition of a solution of sodium boro-
hydride (0.33 g, 8.8 mmol) in ethanol (30 mL). The solution
was allowed to warm to rt and was stirred for 16 h before being
quenched by the addition of water (20 mL). The mixture was
heated to 80 °C for 30 min until the precipitation of boron
salts ceased. The precipitate was removed by filtration and the
filtrate was evaporated under reduced pressure. The resulting
residue was dissolved in water (20 mL) and aq. NaHCO3 satu-
rated solution (30 mL) was added to adjust the pH to approxi-
mately 9. It was then extracted with ethyl acetate (5 × 40 mL).
The combined organic layers were washed with brine
(100 mL), dried (Na2SO4) and the solvent was removed
in vacuo: brown syrup (0.91 g, 76%); 1H NMR (500 MHz,
CDCl3) δ 8.51 (d, J = 4.5 Hz, 1H, Pyr-H), 7.60 (t, J = 7.6 Hz, 1H,
Pyr-H), 7.27–7.23 (m, 3H, Pyr-H, Ar–H), 7.15–7.11 (m, 1H, Pyr-
H), 6.91 (d, J = 8.4 Hz, 2H, Ar–H), 5.24 (m, 2H, H-2, H-4), 5.12
(t, J = 9.3 Hz, 1H, H-3), 5.02 (d, J = 7.1 Hz, 1H, H-1), 4.24 (dd,
J = 12.4, 5.3 Hz, 1H, H-6), 4.13 (dd, J = 12.4, 2.0 Hz, 1H, H-6′),
3.87 (s, 2H, PyrCH2), 3.81 (ddd, J = 7.6, 5.3, 2.0 Hz, 1H, H-5),
3.76 (s, 2H, ArCH2), 2.94 (bs, 1H, N–H), 2.03, 2.02, 2.00, 1.99
(each s, 3H, OAc). 13C NMR (126 MHz, CDCl3) δ 170.7, 170.4,
169.5, 169.4 (each CvO), 159.5 (Pyr-C), 156.2 (Ar–C), 149.4
(Pyr-CH), 136.6 (Pyr-CH), 129.7 (Ar–C), 128.6 (Ar–CH), 122.6
(Pyr-CH), 122.2 (Pyr-CH), 117.2 (Ar–CH), 99.5 (C-1), 72.9 (C-4),
72.2 (C-5), 71.4 (C-3), 68.5 (C-2), 62.1 (C-6), 54.3 (PyrCH2), 52.8
(ArCH2), 20.85, 20.82, 20.77, 20.75 (each OAc). IR (film on
NaCl): 3427, 2945, 3922, 1751, 1610, 1592, 1511, 1474, 1435,
1369, 1214, 1069, 1042, 908, 831, 761, 600 cm−1. HRMS (ESI+):
m/z calculated for C27H32N2O10 + H
+ [M + H+]: 545.2135.
Found: 545.2139. [α]22D : −0.07 (c 0.5, dichloromethane).
Elemental analysis calculated (%) for C27H32N2O2: C 59.55,
H 5.92, N 5.14. Found: C 59.27, H 6.10, N 5.03.
cis-Aquadichloro(N-[4-(hydroxyphenyl)methyl]-2-pyridine-
methamino)copper (3a). Compound 2a (438 mg, 2 mmol) was
dissolved in ethanol (10 mL) and was added to a solution of
CuCl2·2H2O (348 mg, 2 mmol) in ethanol (15 mL). A green pre-
cipitate was formed and the reaction was allowed to stir at
rt overnight. The solvent was reduced by half in vacuo and was
then cooled on ice for 30 min and a green solid was collected
by vacuum filtration. This was washed with cold ethanol and
dried under vacuum: green solid (526 mg, 69%). Mp 178 °C.
IR (KBr disk): 3495, 3377, 3198, 2970, 2918, 2873, 1610, 1516,
1484, 1444, 1234, 1217, 1049, 823, 768, 579, 510 cm−1. Magnetic
moment: 1.78 B.M. Elemental analysis calculated (%) for
C13H16N2Cl2O2Cu: C 42.58, H 4.40, N 7.64. Found: C 42.66,
H 4.39, N 7.30 (X-ray crystallography, see section 4.1-ESI†).
cis-Dichloro(N-{[4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)
pheny]lmethyl}-2-pyridinemethamino)copper (3b). Compound
2b (294 mg, 0.54 mmol) was dissolved in ethanol (10 mL) at rt
and was added to a solution of CuCl2·2H2O (110 mg,
0.65 mmol) in ethanol (10 mL). The reaction was allowed to
stir overnight. The resulting green solution was allowed to
stand for 3 days. A green precipitate formed and was collected
by vacuum filtration. This was washed with cold ethanol
and dried under vacuum: green solid (216 mg, 59%).
Mp 146–147 °C. IR (KBr disk): 3456, 3233, 2998, 2941, 2887,
1753, 1628, 1610, 1512, 1486, 1447, 1431, 1376, 1231, 1045,
908, 769, 600 cm−1. Magnetic susceptibility: 1.81 B.M.
Elemental analysis calculated (%) for C27H32N2Cl2O10Cu:
C 47.76, H 4.75, N 4.13. Found: C 47.46, H 4.85, N 3.82.
Dalton Transactions Paper
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Bis(N-[4-(hydroxyphenyl)methyl]-2-pyridinemethamino)zinc
perchlorate monohydrate (4). To a solution of N-[4-(hydroxy-
phenyl)methyl]-2-pyridinemethamine 2a (397 mg, 1.8 mmol)
in ethanol (10 mL) was added a solution of Zn(ClO4)2·6H2O
(229 mg, 0.6 mmol) in ethanol (10 mL) at rt to immediately
yield a beige precipitate. This was stirred for 5 h and the pre-
cipitate was collected by vacuum filtration to yield a hygro-
scopic brown solid. This was then lyophilized for 48 h to yield
the product: beige solid (lyophilized after filtration, 207 mg,
62%). Mp: 161–163 °C. 1H NMR (500 MHz, CDCl3) δ 8.11 (bs
1H) 8.03 (bs, 1H), 7.49 (bs, 1H), 7.09 (bs, 2H), 6.77 (bs, 2H,
Ar–H), 3.91 (s, 2H, Pyr-CH2), 3.64 (Ar–CH2).
13C NMR
(126 MHz, DMSO) δ 157.1 (Pyr-C), 148.1 (Ar–C), 147.3 (Pyr-CH),
140.4 (Pyr-CH), 130.5 (Pyr-CH), 130.2 (Ar–C), 124.1 (Ar–CH),
115.7 (Ar–CH), 56.6 (CH2), 52.0 (CH2). IR (KBr disk): 3430,
2935, 2968, 1613, 1574, 1517, 1489, 1446, 1375, 1269, 1222,
1177, 1108, 1051, 928, 833, 764, 623, 509 cm−1. Elemental ana-
lysis calculated (%) for C26H30N4Cl2O11Zn: C 43.93, H 4.25,
N 7.88. Found: C 44.02, H 4.49, N 8.20.
2-Hydroxy-4-[2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)
ethoxy]benzaldehyde (5d). To a solution of 2-chloroethyl
2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside53 (1 g, 2.4 mmol) and
sodium iodide (359 mg, 2.4 mmol) in anhydrous acetonitrile
(15 mL) was added a solution of 2,4-dihydroxybenzaldehyde
(660 mg, 4.8 mmol) and DBU (0.359 mL, 2.4 mmol) in anhy-
drous acetonitrile (10 mL). The mixture was sealed in a micro-
wave tube under argon and heated under microwave
irradiation to 125 °C for 4 h. The solvent was then removed
in vacuo and the residue was dissolved in dichloromethane
(20 mL) and washed with water (2 × 20 mL), aq. Na2S2O4 1 M
solution (20 mL), aq. NaHCO3 saturated solution (2 × 20 mL),
brine (20 mL) and dried (Na2SO4). The solvent was removed in
the rotatory evaporator to yield a brown oil which was purified
by column chromatography (3 : 1 petroleum ether/ethyl
acetate, Rf: 0.17): dark yellow oil (862 mg, 66%).
1H NMR
(500 MHz, CDCl3) δ 11.39 (s, 1H, OH), 9.67 (s, 1H, HCvO),
7.40 (d, J = 8.7 Hz, 1H, Ar–H), 6.49 (dd, J = 8.7, 2.3 Hz, 1H, Ar–
H), 6.36 (d, J = 2.3 Hz, 1H, Ar–H), 5.18 (t, J = 9.6 Hz, 1H, H-3),
5.05 (t, J = 9.7 Hz, 1H, H-4), 4.97 (dd, J = 9.6, 8.0 Hz, 1H, H-2),
4.61 (d, J = 8.0 Hz, 1H, H-1), 4.22 (dd, J = 12.3, 4.7 Hz, 1H,
H-6), 4.16–4.05 (m, 4H, H-6′,OCH, CH2Cl), 3.91 (dt, J = 9.6, 3.5
Hz, 1H, OCH′), 3.69 (ddd, J = 9.7, 4.7, 2.4 Hz, 1H, H-5), 2.03,
1.98, 1.95, 1.91 (each s, 3H, OAc). 13C NMR (126 MHz, CDCl3)
δ 194.4 (HCvO), 170.6, 170.2, 169.4, 169.3 (each CvO), 165.7
(Ar–C), 164.4(Ar–C), 135.4 (Ar–CH), 115.4 (Ar–C), 108.4
(Ar–CH), 101.3(Ar–CH), 101.0 (C-1), 72.7 (C-3), 71.9 (C-5), 71.1
(C-4), 68.3 (C-2), 67.7 (C-6), 67.4 (CH2OAr), 61.8 (OCH2), 20.7,
20.6, 20.5, 20.5 (each OAc). IR (KBr disk): 3471, 2967, 1745,
1633, 1581, 1430, 1379, 1230, 1123, 1044, 989 cm−1. HRMS
(ESI+): m/z calculated for C23H29O13 + H
+ [M + H+]: 513.1608.
Found: 513.1609. [α]25D : −0.11° (c 1, methanol).
General procedure for imine ligand synthesis (N2O series)
2-Picolylamine and the corresponding aldehyde (1 equiv.) were
dissolved in ethanol (∼0.3 M). The reaction mixture was
allowed to stir at rt until TLC analysis showed disappearance
of the starting material (∼4–6 h). The solvent was reduced by
half in a rotatory evaporator and cooled on ice to enhance pre-
cipitation if required. The precipitate was collected by fil-
tration, washed with cold ethanol and dried under vacuum.
4-{[(2-Methylpyridinyl)-E-imino]methyl}-benzene-1,3-diol (6a).
Yellow solid (3.12 g, 95%). Mp: 159–160 °C. 1H NMR
(500 MHz, CDCl3) δ 8.60 (d, J = 4.9 Hz, 1H, Pyr-H), 8.25 (s, 1H,
C(vN)H), 7.77 (dd, J = 8.5, 6.9 Hz, 1H, Pyr-H), 7.42 (d, J = 7.8
Hz, 1H, Pyr-H), 7.35–7.26 (m, 1H, Pyr-H), 6.87 (d, J = 8.4 Hz,
1H, Ar–H), 6.29 (d, J = 2.2 Hz, 1H, Ar–H), 6.20 (dd, J = 8.4, 2.2
Hz, 1H, Ar–H), 4.83 (s, 2H, CH2).
13C NMR (126 MHz, CDCl3)
δ 166.1 (Ar–C), 164.2 (Ar–C), 161.1 (CvN), 157.7 (Pyr-C), 148.9
(Pyr-CH), 137.8 (Pyr-CH), 133.4 (Ar–CH), 123.2 (Pyr-CH), 123.0
(Pyr-CH), 112.3 (Ar–C), 107.3 (Ar–CH), 103.3 (Ar–CH), 63.9
(CH2). IR (KBr disk): 3435, 3064, 2763, 2676, 2618, 1621, 1442,
1331, 1271, 1120 cm−1. HRMS (ESI+): m/z calculated for
C13H12N2O2 [M
+]: 228.0899. Found. 228.0905. Elemental ana-
lysis calculated (%) for C13H12N2O2: C 68.41, H 5.30, N 12.27.
Found: C 68.63, H 5.44, N 12.28 (X-ray crystallography, see
section 4.2-ESI†).
5-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-2-{[(2-methyl-
pyridinyl)-E-imino]methyl}phenol (6b). Orange solid (1.12 g,
95%). Mp: 77–78 °C. 1H NMR (500 MHz, CDCl3) δ 13.72 (s, 1H,
OH), 8.58 (d, J = 4.9 Hz, 1H, Pyr-H), 8.45 (s, 1H, C(H)vN), 7.69
(td, J = 7.8, 1.9 Hz, 1H, Pyr-H), 7.34 (d, J = 7.8 Hz, 1H, Pyr-H),
7.21 (m, 2H, Pyr-H, Ar–H), 6.56 (d, J = 2.3 Hz, 1H, Ar–H), 6.50
(dd, J = 8.5, 2.3 Hz, 1H, Ar–H), 5.36–5.20 (m, 2H, H-1, H-2),
5.14 (m, 2H, H-3, H-4), 4.91 (s, 2H, CH2-Pyr), 4.29 (dd, J = 12.3,
5.7 Hz, 1H, H-6), 4.18 (dd, J = 12.3, 2.3 Hz, 1H, H-6′), 3.89
(ddd, J = 10.1, 5.7, 2.3 Hz, 1H, H-5), 2.10, 2.07, 2.05, 2.04 (each
s, 3H, OAc). 13C NMR (126 MHz, CDCl3) δ 170.8, 170.3, 169.5,
169.4 (each CvO), 165.9 (CvN), 163.8 (Pyr-C), 160.2 (Ar–C),
157.9 (Ar–C), 149.6 (Pyr-CH), 137.0 (Pyr-CH), 132.9 (Ar–CH),
122.5 (Pyr-CH), 122.0 (Pyr-CH), 114.6 (Ar–C), 108.2 (Ar–CH),
104.2 (Ar–CH), 98.3 (C-1), 72.8 (C-2), 72.3 (C-3), 71.1 (C-5), 68.3
(C-4), 64.6 (CH2-Pyr), 61.9 (C-6), 20.8, 20.7, 20.7, 20.7 (each
OAc). IR (KBr disk): 3472, 3053, 3017, 2965, 2870, 1749, 1635,
1589, 1505, 1368, 1255, 1227, 1176, 1079, 1056, 749 cm−1.
HRMS (ESI+): m/z calculated for C27H30N2O11 + H
+ [M + H+]:
559.1928. Found: 559.1895. [α]23D : −0.23° (c 2, dichloro-
methane). Elemental analysis calculated (%) for C27H30N2O11:
C 58.06, H 5.41, N 5.02. Found: C 58.24, H 5.42, N 5.25.
5-(2-Hydroxyethoxy)-2-{[(2-methylpyridinyl)-E-imino]methyl}
phenol (6c). Yellow solid (1.22 g, 86%). Mp: 124 °C. 1H NMR
(500 MHz, CDCl3) δ 13.83 (s, 1H, Ar-OH), 8.58 (d, J = 4.9 Hz,
1H, Pyr), 8.41 (s, 1H, C(vN)H), 7.69 (td, J = 7.7, 1.8 Hz, 1H,
Pyr), 7.35 (d, J = 7.7 Hz, 1H, Ar–H), 7.22–7.20 (m, 1H, Ar–H),
7.18 (d, J = 8.9 Hz, 1H, Ar–H), 6.46 (m, 2H, Ar–H), 6.44 (d, J =
2.4 Hz, 1H, Ar–H), 4.89 (s, 2H, Pyr-CH2), 4.18–4.06 (t, J =
4.9 Hz, 2H, ArO–CH2), 4.01–3.92 (t, J = 4.9 Hz, 2H, CH2OH).
13C NMR (126 MHz, CDCl3) δ 165.8 (CvN), 164.5 (Ar–C), 162.6
(Ar–C), 158.1 (Pyr-C), 149.4 (Pyr-CH), 136.9 (Pyr-CH), 132.9
(Ar–CH), 122.4 (Pyr-CH), 121.9 (Pyr-CH), 112.9 (Ar–C), 106.8
(Ar–CH), 101.9 (Ar–CH), 69.3 (ArOCH2), 64.2 (Pyr-CH2), 61.3
(CH2OH). IR (KBr disk): 3406, 3269, 2943, 2927, 2896, 1630,
1596, 1179.5, 1138, 1096, 1044, 844, 763, 614 cm−1. HRMS
Paper Dalton Transactions
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(ESI+): m/z calculated for C15H16N2O3 + H
+ [M + H+]: 273.1239.
Found: 273.1233. Elemental analysis calculated (%) for
C15H14N2O3: C 66.54, H5.92, N 10.29. Found: C 66.35, H 6.05,
N 10.26 (X-ray crystallography, see section 4.3-ESI†).
5-[2-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)ethoxy]-2-
{[(2-methylpyridinyl)-E-imino]methyl}phenol (6d). Pale
yellow solid (1.13 g, 78%). Mp: 118–119 °C. 1H NMR (500 MHz,
CDCl3) δ 13.80 (s, 1H, Ar-OH), 8.58 (d, J = 4.0 Hz, 1H, Pyr-H),
8.41 (s, 1H, C(H)vN), 7.69 (td, J = 7.7, 1.8 Hz, 1H, Pyr-H), 7.35
(d, J = 7.8 Hz, 1H, Pyr-H), 7.21 (dd, J = 7.0, 5.4 Hz, 1H, Pyr-H),
7.19–7.14 (m, 1H, Ar–H), 6.44–6.39 (m, 2H, Ar–H), 5.22 (t, J =
9.6 Hz, 1H, H-3), 5.10 (t, J = 9.7 Hz, 1H, H-4), 5.02 (dd, J = 9.6,
8.0 Hz, 1H, H-2), 4.89 (s, 2H, CH2-Pyr), 4.66 (d, J = 8.0 Hz, 1H,
H-1), 4.27 (dd, J = 12.3, 4.7 Hz, 1H, H-6), 4.19–4.06 (m, 4H,
H-6′, OCH2CH2OAr, OCHCH2OAr), 4.01–3.86 (m, 1H, OCH′
CH2OAr), 3.72 (ddd, J = 10.1, 4.7, 2.4 Hz, 1H, H-5), 2.08, 2.03,
2.00, 1.96 (each s, 3H, OAc). 13C NMR (126 MHz, CDCl3)
δ 170.8, 170.4, 169.5, 169.5 (each CvO), 165.8 (CvN), 164.5
(Ar–C), 162.5 (Ar–C), 158.2 (Pyr-C), 149.5 (Pyr-CH), 136.9 (Pyr-
CH), 133.1 (Ar–CH), 122.5 (Pyr-CH), 121.9 (Pyr-CH), 112.9
(Ar–C), 106.8 (Ar–CH), 101.8 (Ar–CH), 101.2 (C-1), 72.8 (C-3),
72.0 (C-5), 71.2 (C-2), 68.4 (C-4), 68.1 (CH2OAr), 67.2 (OCH2),
64.2 (CH2-Pyr), 61.9 (C-6), 20.8, 20.7, 20.7, 20.7 (each OAc).
IR (KBr disk): 3438, 2964, 2935, 2885, 1744, 1630, 1591, 1518,
1433, 1370, 1254, 1224, 1178, 1141, 1093, 1046, 981, 846,
606 cm−1. HRMS (ESI+): m/z calculated for C29H34N2O12 + H
+
[M + H+]: 603.2190. Found: 603.2177. [α]23D : −0.16° (c 2,
dichloromethane). Elemental analysis calculated (%) for
C29H34N2O12: C 57.80, H 5.69, N 4.65. Found: C 58.04, H 5.68,
N 4.65.
General procedure for metal complexation (N2O series)
The imino ligand was dissolved in ethanol (∼2 M) and added
to a solution of the corresponding salt (0.5 equiv. for 7,
1 equiv. for 8, ∼2 M) in ethanol. The reaction mixture was
allowed to reflux for 5 h (for complex 7) or 3 h (for complex 8)
under nitrogen. The solvent was reduced by half in a rotatory
evaporator and cooled on ice to enhance precipitation. The
precipitate was collected by filtration, washed with cold
ethanol and dried under vacuum.
Aqua(5-hydroxy-2-{[(2-methylpyridinyl)-E-imino]methyl}pheno-
ate)copper perchlorate dihydrate (7). Green solid (158 mg,
40%). Mp: 189–191 °C. IR (KBr Disk): 3454, 3208, 3121, 2938,
2913, 2021, 1636, 1615, 1541, 1490, 1334, 1231, 1170, 1057,
625 cm−1. Magnetic susceptibility: 1.77 B.M. Elemental ana-
lysis calculated (%) for C13H23N2ClO9Cu: C 35.14, H 3.86,
N 6.31. Found: C 34.96, H 3.75, N 6.79.
(5-Hydroxy-2-{[(2-methylpyridinyl)-E-imino]methyl}phenolate)
zinc perchlorate monohydrate (8). Yellow solid (859 mg, 65%,
stored under argon). Mp: 107–109 °C. 1H NMR (500 MHz,
CD3CN) δ 8.52 (bs, 2H Pyr-H, HC(vN)), 8.11 (bs, 1H, Pyr-H),
7.61 (bs, 2H, Pyr-H), 7.44 (bs, 1H Ar–H), 6.60 (bs, 2H, Ar–H),
5.08 (bs, 2H, CH2), 3.81 (bs, H2O, OH). IR (KBr disk): 3437,
3335, 3278, 3090, 2954, 2011, 1611, 1589, 1489, 1439, 1381,
1293, 1089, 1027, 625 cm−1. Mp: 107–109 °C Elemental ana-
lysis calculated (%) for C13H15N2ClO8Zn: C 38.07, H 3.20,
N 8.65. Found: C 37.89, H 3.31, N 8.40. A satisfactory 13C NMR
spectrum could not to be obtained due to the hydrolysis of the
compound over the time scale necessary to obtain the data.
Bis(2-picolylamine)zinc perchlorate (9). Zn(ClO4)2·6H2O
(723 mg, 1.9 mmol) and 2-picolylamine (0.4 mL, 3.8 mmol)
were stirred at rt in ethanol (20 mL) for 4 h and cooled on ice
for 30 min. This yielded a white precipitate which was col-
lected by vacuum filtration, washed with cold ethanol and
dried under vacuum: white solid (855 mg, 94%). Mp:
Compound decomposes at 245 °C. 1H NMR (500 MHz, DMSO)
δ 8.30 (d, J = 2.9 Hz, 2H, Pyr-H), 8.05 (t, J = 7.2 Hz, 2H, Pyr-H),
7.59 (d, J = 7.9 Hz, 2H, Pyr-H), 7.56–7.50 (m, 2H, Pyr-H), 4.08
(s, 4H, CH2), 3.91 (s, 4H, NH2).
13C NMR (126 MHz, DMSO)
δ 157.4 (Pyr-C), 146.8 (Pyr-CH), 139.7 (Pyr-CH), 123.8 (Pyr-CH),
123.5 (Pyr-CH), 42.6 (CH2). IR (KBr disk): 3439, 3281, 3204,
3133, 2912, 1603, 1590, 1569, 1487, 1439, 1383, 1334, 1294,
1141, 1114, 1090, 1032, 1017, 940, 772, 636, 626 cm−1.
Elemental analysis calculated (%) for C12H16N4Cl2O8Zn:
C 29.99, H 3.36, N 11.6. Found: C 29.51, H, 3.32, N 11.45.
Biological assays
Cultivation of mammalian cells. The LLC-MK2 epithelial
cells and RAW 264.7 murine macrophages were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% of fetal bovine serum (FBS) at 37 °C in an atmo-
sphere containing 5% CO2.
Murine macrophage viability assay. The effect of each com-
pound on RAW 264.7 murine macrophages viability was evalu-
ated by MTT assay. Firstly, macrophage cells (105 mL−1) were
allowed to adhere in 96-well tissue culture plates for 24 h at
37 °C, in a 5% CO2 atmosphere. Non-adherent cells were
removed by washes with PBS and the wells refilled with DMEM
medium supplemented with 10% FBS. The macrophages were
then incubated with increasing concentration of the test com-
pounds (0.39 to 400 µM) and incubated for additional 24 h at
37 °C, in a 5% CO2 atmosphere. Subsequently, the culture
medium was discharged and the formation of formazan was
measured by adding MTT (5 mg mL−1 in PBS, 50 µg per well)
and incubating the wells for 3 h in the dark at 37 °C. The
plates were subsequently centrifuged at 1300 rpm for
8 minutes, the supernatant was removed, the pellet was dis-
solved in 200 mL of DMSO and the absorbance measured in
an ELISA reader at 570 nm (Bio-Tek Instruments). The 50%
cytotoxicity inhibitory concentration (CC50) was determined by
linear regression analysis.
Parasites and cultivation. Tissue culture trypomastigote
forms of T. cruzi Y strain, which was isolated from a human
case, were obtained from the supernatants of infected
LLC-MK2 epithelial cells after 5 days of incubation in DMEM
supplemented with 2% heat-inactivated fetal bovine serum
(FBS) at 37 °C in a humidified 5% CO2. L. amazonensis (Josefa
strain) promastigotes were maintained by weekly transfers in
25 cm3 culture flasks with Schneider’s insect medium, pH 7.0,
supplemented with 10% FBS at 28 °C.
T. cruzi viability. The effects of the compounds (Fig. 1) on
T. cruzi trypomastigotes were assessed by incubation of the
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parasites in DMEM with 2% heat-inactivated FBS. Briefly, try-
pomastigotes were counted using a Neubauer chamber and
resuspended in fresh medium to a final concentration of 106
viable cells per mL. The viability was assessed by motility and
lack of Trypan blue staining. Each compound was added to the
culture at final concentrations ranging from 0.1 to 50 µM.
After incubation for 24 h at 37 °C, the number of motile para-
sites was quantified under light microscopy. The 50% lethal
dose (LD50) was determined after 24 h by linear regression.
The simple salts ZnCl2 and CuCl2·2H2O and dimethylsulfoxide
(DMSO) were used as appropriated controls.
L. amazonensis viability. The effects of the compounds
(Fig. 1) on L. amazonensis promastigotes were assessed by incu-
bation in Schneider’s insect medium with 10% FBS at 28 °C.
Briefly, promastigotes were counted using a Neubauer
chamber and resuspended in fresh medium to a final concen-
tration of 105 viable cells per milliliter. The viability was
assessed by motility and lack of Trypan blue staining. Each
compound was added to the culture at final concentrations
ranging from 0.1 to 50 µM. After incubation for 72 h at 28 °C,
the number of motile parasites was quantified. The 50%
inhibitory concentration (IC50) was determined after 72 h by
linear regression analysis. The simple salts ZnCl2 and CuCl2
and DMSO were used as appropriate controls.
T. cruzi and L. amazonensis morphology. Light microscopy
analysis was performed in order to detect some possible altera-
tions on the morphology of T. cruzi trypomastigotes and
L. amazonensis promastigotes after the treatment with the most
efficacious compounds at LD50 (or IC50) concentration. In this
context, the parasites were washed in phosphate-buffered saline
(PBS; 150 mM NaCl, 20 mM phosphate buffer, pH 7.2), fixed
with methanol, Giemsa-stained for 1 h and then observed in a
Zeiss microscope (Axioplan, Oberkochen, Germany).
G. mellonella viability. Sixth instar larvae of G. mellonella
(the greater wax moth, which belongs to order Lepidoptera,
family Pyralidae) were obtained from The Mealworm Company
(Sheffield, England) and stored in wood shavings in the dark
at 15 °C. Larvae chosen for experiments weighed between
0.17–0.23 g and displayed no discoloration on their cuticle.
Five healthy larvae inoculated with each compound and were
placed in sterile 9 cm Petri dishes containing a sheet of
Whatman filter paper and a small amount of wood shavings.
Larvae were incubated at 30 °C and survival was assessed at
24 h and 48 h by response to physical stimulus. Compounds
2a–b, 3a–b, 4, 6a–b, and 8 were chosen for analysis and were
tested at concentrations of 1, 10 and 100 μM. These were admi-
nistered as solutions in 10% DMSO in PBS buffer by inocu-
lation of the larvae through the last left proleg directly into the
hemocoel using a 300 μL Thermo Myjector syringe (29G) with
the sterile test solutions (20 μL).
Statistics. All experiments were performed in triplicate, in
three independent experimental sets. The data were analyzed
statistically by means of Student’s t-test using EPIINFO 6.04
(Database and Statistics Program for Public Health) computer
software. P values of 0.05 or less were considered statistically
significant.
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